Exploring human biology with N-of-1 clinical trials
Cambridge Prisms: Precision Medicine · 2023 · 1
DOI: 10.1017/pcm.2022.15 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cambridge Prisms: Precision Medicine, online erschienen am 10.01.2023. Verfasst von N J Schork und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Quantitative Medicine, The Translational Genomics Research Institute (TGen), Phoenix, AZ, USA. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NCI NIH HHS, National Institute on Aging.
Abstract (Originalsprache)
Studies on humans that exploit contemporary data-intensive, high-throughput ‘omic’ assay technologies, such as genomics, transcriptomics, proteomics and metabolomics, have unequivocally revealed that humans differ greatly at the molecular level. These differences, which are compounded by each individual’s distinct behavioral and environmental exposures, impact individual responses to health interventions such as diet and drugs. Questions about the best way to tailor health interventions to individuals based on their nuanced genomic, physiologic, behavioral, etc. profiles have motivated the current emphasis on ‘precision’ medicine. This review’s purpose is to describe how the design and execution of N-of-1 (or personalized) multivariate clinical trials can advance the field. Such trials focus on individual responses to health interventions from a whole-person perspective, leverage emerging health monitoring technologies, and can be used to address the most relevant questions in the precision medicine era. This includes how to validate biomarkers that may indicate appropriate activity of an intervention as well as how to identify likely beneficial interventions for an individual. We also argue that multivariate N-of-1 and aggregated N-of-1 trials are ideal vehicles for advancing biomedical and translational science in the precision medicine era since the insights gained from them can not only shed light on how to treat or prevent diseases generally, but also provide insight into how to provide real-time care to the very individuals who are seeking attention for their health concerns in the first place.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Quantitative Medicine, The Translational Genomics Research Institute (TGen), Phoenix, AZ, USA.
- Net. bio Inc., Los Angeles, CA, USA.
- University of Chicago, Chicago, IL, USA.
- The University of California Los Angeles, Los Angeles, CA, USA.
ORCID-Profile: N J Schork, L H Goetz
Förderung
- NIA NIH HHS
- NCI NIH HHS
- National Institute on Aging
Zitieren
APA
Schork, N. J., Beaulieu-Jones, B., Liang, W. S., Smalley, S., & Goetz, L. H. (2023). Exploring human biology with N-of-1 clinical trials. Cambridge Prisms: Precision Medicine, 1. https://doi.org/10.1017/pcm.2022.15
Vancouver
Schork NJ, Beaulieu-Jones B, Liang WS, Smalley S, Goetz LH. Exploring human biology with N-of-1 clinical trials. Cambridge Prisms: Precision Medicine. 2023;1. doi:10.1017/pcm.2022.15
BibTeX
@article{Schork2023,
author = {Schork, N J and Beaulieu-Jones, B and Liang, W S and Smalley, S and Goetz, L H},
title = {Exploring human biology with N-of-1 clinical trials},
journal = {Cambridge Prisms: Precision Medicine},
year = {2023},
volume = {1},
doi = {10.1017/pcm.2022.15}
}
EUVIMED